Name: Latest research reports of Ajanta Pharma Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Ajanta Pharma Ltd.
Rating: 5
Author: Motilal Oswal

Ajanta Pharma Ltd.

NSE: AJANTPHARM | BSE: 532331 | ISIN: INE031B01049 | Industry: Pharmaceuticals
| Expensive Performer

3259.9000 -39.00 (-1.18%)

NSE Oct 21, 2026 15:29 PM

36.86% Gain from 52W Low

Volume: 53,439

Ajanta Pharma Ltd.

05 May 2026

3259.90

-1.18%

Strong beat on our 4Q estimates; robust outlook

Buy: Ajanta Pharma Ltd.

Motilal Oswal

Ajanta Pharma (AJP) delivered a better-than-expected 4QFY26, with a 10%/17%/21% beat on our revenue/EBITDA/PAT estimates.

Ajanta Pharma has gained 33.81% in the last 1 Year